L. Zimmerman

Azacitidine (AZA) Treatment Prolongs Overall Survival (OS) in Higher-Risk MDS Patients Compared with Conventional Care Regimens (CCR): Results of the AZA-001 Phase III Study.

J. Byrd, G. Mufti, J. Bennett, 2007 .

Azacitidine Prolongs Overall Survival (OS) and Reduces Infections and Hospitalizations in Patients (Pts) with WHO-Defined Acute Myeloid Leukemia (AML) Compared with Conventional Care Regimens (CCR)

L. Silverman, G. Mufti, P. Fenaux, 2008 .

Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study.

Valeria Santini, Robert Schoch, Pierre Fenaux, 2009, The Lancet. Oncology.

Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia.

H. Dombret, G. Mufti, P. Fenaux, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Effi cacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes : a randomised , open-label , phase III study

J. Byrd, G. Mufti, J. Bennett, 2012 .

Results of a phase 2, multicenter, single‐arm, open‐label study of lenalidomide in pediatric patients with relapsed or refractory acute myeloid leukemia

T. Alonzo, P. Brown, J. Levine, 2021, Pediatric blood & cancer.